Innovent Biologics, Inc. (1801.HK)

HKD 36.2

(-0.82%)

Operating Income Summary of Innovent Biologics, Inc.

Innovent Biologics, Inc.'s latest annual operating income in 2023 was -1.67 Billion CNY , up 19.03% from previous year.
Innovent Biologics, Inc.'s latest quarterly operating income in 2024 Q2 was -370.34 Million CNY , down 0.0% from previous quarter.
Innovent Biologics, Inc. reported an annual operating income of -2.07 Billion CNY in 2022, up 33.38% from previous year.
Innovent Biologics, Inc. reported an annual operating income of -3.11 Billion CNY in 2021, down -279.55% from previous year.
Innovent Biologics, Inc. reported a quarterly operating income of -370.34 Million CNY for 2024 Q2, down 0.0% from previous quarter.
Innovent Biologics, Inc. reported a quarterly operating income of -422.54 Million CNY for 2023 Q3, down -17.56% from previous quarter.

Annual Operating Income Chart of Innovent Biologics, Inc. (2023 - 2016)

Historical Annual Operating Income of Innovent Biologics, Inc. (2023 - 2016)

Year	Operating Income	Operating Income Growth
2023	-1.67 Billion CNY	19.03%
2022	-2.07 Billion CNY	33.38%
2021	-3.11 Billion CNY	-279.55%
2020	-820.13 Million CNY	50.69%
2019	-1.66 Billion CNY	6.86%
2018	-1.78 Billion CNY	-138.04%
2017	-750.13 Million CNY	-62.53%
2016	-461.53 Million CNY	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	-370.34 Million CNY	22.88%
2024 Q2	-370.34 Million CNY	0.0%
2023 Q3	-422.54 Million CNY	-17.56%
2023 Q1	-359.42 Million CNY	57.06%
2023 Q2	-359.42 Million CNY	0.0%
2023 Q4	-480.22 Million CNY	-13.65%
2023 FY	-1.67 Billion CNY	19.03%
2022 Q2	-724.46 Million CNY	0.0%
2022 Q4	-836.96 Million CNY	0.0%
2022 FY	-2.07 Billion CNY	33.38%
2022 Q3	-836.96 Million CNY	-15.53%
2022 Q1	-724.46 Million CNY	15.86%
2021 Q4	-860.99 Million CNY	0.0%
2021 Q3	-860.99 Million CNY	-75.47%
2021 Q2	-490.67 Million CNY	0.0%
2021 Q1	-490.67 Million CNY	-546.53%
2021 FY	-3.11 Billion CNY	-279.55%
2020 FY	-820.13 Million CNY	50.69%
2020 Q4	109.88 Million CNY	0.0%
2020 Q3	109.88 Million CNY	128.29%
2020 Q2	-388.47 Million CNY	0.0%
2020 Q1	-388.47 Million CNY	29.09%
2019 FY	-1.66 Billion CNY	6.86%
2019 Q1	-361.93 Million CNY	32.33%
2019 Q3	-547.87 Million CNY	-51.38%
2019 Q4	-547.87 Million CNY	0.0%
2019 Q2	-361.93 Million CNY	0.0%
2018 Q1	-249.4 Million CNY	-32.03%
2018 Q4	-534.86 Million CNY	0.0%
2018 Q3	-534.86 Million CNY	-114.46%
2018 Q2	-249.4 Million CNY	0.0%
2018 FY	-1.78 Billion CNY	-138.04%
2017 Q1	-123.47 Million CNY	0.0%
2017 FY	-750.13 Million CNY	-62.53%
2017 Q4	-188.89 Million CNY	0.0%
2017 Q3	-188.89 Million CNY	-52.98%
2017 Q2	-123.47 Million CNY	0.0%
2016 FY	-461.53 Million CNY	0.0%

Peer Operating Income Comparison of Innovent Biologics, Inc.

Name	Operating Income	Operating Income Difference
Uni-Bio Science Group Limited	67.76 Million HKD	2578.015%
CK Life Sciences Int'l., (Holdings) Inc.	897.95 Million HKD	287.014%